Endocrine Abstracts

The prevalence of prediabetes is increasing in the global population and its metabolic derangements may expose to a higher risk to develop type 2 diabetes (T2D) and its cardiovascular burden. Lifestyle modifications might have considerable benefits on ameliorating metabolic status. In light of this scenario, preventive programmes are focusing on the modification of lifestyle that notoriously decreases the incidence of T2D, to reduce the risk and delay T2D and its burden: Diabe...

Weight loss in individuals with Obesity (O) and Type 2 Diabetes (T2D), may improve glycaemic control and weight-related comorbidities, and in some cases, induce diabetes remission. However, body weight control is generally an unmet aim in this population. Thus, there is an increasing need to consider pharmacological approaches to assist weight loss in diabetes-obesity. Glucose-lowering agents as the sodium-glucose co-Transporter 2 inhibitors (SGLT2i) and GLP-1 Receptor Agonist...

Glycemic variability (GV), a complex phenomenon affecting subjects with diabetes, is one of the main contributors to the risk to develop both acute and long-term complications in type 1 (T1D) and type 2 (T2D) subjects. DNA double-strand breaks, apoptosis, overgeneration of reactive oxygen species (ROS) and the induction of some regulatory micro-RNAs, sustain the ominous mechanisms mainly attributable to GV. The characteristic cellular phenotype induced by GV is scarcely define...